Biologics Selected as Exclusive Specialty Pharmacy Provider for CAMCEVI

Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Accord BioPharma, Inc. as an exclusive specialty pharmacy provider for CAMCEVI (leuprolide) 42mg injection emulsion, for subcutaneous use.

Approved by the U.S. Food and Drug Administration (FDA) on May 25, 2021, CAMCEVI is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer.

Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care.

With a focus on improving the patient experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patients’ perspective and develop high-quality therapies that impact patients’ lives.

Accord BioPharma believes in the ability of biosimilars to increase access and options for patients and deliver savings to the U.S. healthcare system, and is striving to offer one of the deepest biosimilar portfolios in the industry.

Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach.

In 2021, EVERSANA and Accord BioPharma announced a partnership to support the launch of CAMCEVI. Accord BioPharma was leading the distribution in the United States.

Intas Pharmaceuticals (Intas) is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world.

Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year.

Accord BioPharma offers eligible patients commercial copay assistance solutions, patient assistance programs, and a nurse-staffed clinical hotline that provides answers to questions from patients. The company also offers healthcare professionals access to AccordConnects, a mobile application designed to help healthcare practices manage in-practice inventory

EVERSANA provides multiple services to Accord BioPharma for CAMCEVI, including field deployment solutions, training, and the company’s comprehensive data and analytics platform. EVERSANA also provides additional services to Accord BioPharma as part of the commercialization agreement.